Valiant Laboratories (NSE:VALIANTLAB) 1-Year Sharpe Ratio: -0.59 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VALIANTLAB Valiant Laboratories Ltd NSE:VALIANTLAB
52 GF Score
Price ₹63.44
GF Value ₹101.97
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Valiant Laboratories 1-Year Sharpe Ratio?

Valiant Laboratories NSE:VALIANTLAB -0.25% 52 1-Year Sharpe Ratio is -0.59 as of Jul. 18, 2026. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 52/100 and a GF Value™ of ₹101.97 (Possible Value Trap). The stock has 5 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-18), Valiant Laboratories's 1-Year Sharpe Ratio is -0.59.

Valiant Laboratories  (NSE:VALIANTLAB) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Valiant Laboratories 1-Year Sharpe Ratio Related Terms

NSE:VALIANTLAB vs ZTS, UTHR: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valiant Laboratories 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's 1-Year Sharpe Ratio falls into.


NSE:VALIANTLAB
52GF Score
Valiant Laboratories Ltd NSE:VALIANTLAB
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valiant Laboratories 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.59 mean?
Valiant Laboratories (NSE:VALIANTLAB) has a 1-Year Sharpe Ratio of -0.59 as of Jul. 18, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Valiant Laboratories and its competitors.
Is Valiant Laboratories' 1-Year Sharpe Ratio too high?
Valiant Laboratories' current 1-Year Sharpe Ratio is -0.59. Overall, Valiant Laboratories has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' 1-Year Sharpe Ratio compare to ZTS and UTHR?
Valiant Laboratories' 1-Year Sharpe Ratio of -0.59 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Valiant Laboratories and its competitors. Valiant Laboratories's current 1-Year Sharpe Ratio is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹101.97, compared to a current price of ₹63.44 — trading 37.8% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.59. Valiant Laboratories' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current 1-Year Sharpe Ratio is -0.59 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued. The current stock price of ₹63.44 is trading 37.8% below its estimated GF Value™ of ₹101.97. GuruFocus considers Valiant Laboratories to be Possible Value Trap.

Key valuation signals for NSE:VALIANTLAB:

  • 1-Year Sharpe Ratio: -0.59
  • GF Value™: ₹101.97 vs. price of ₹63.44 (37.8% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valiant Laboratories Business Description

Other Exchanges 543998:India
Address Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
52GF Score

Get the complete analysis for NSE:VALIANTLAB

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹63.44
Price
₹101.97
GF Value